AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01335854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Access to CPAP Data with Financial Incentive
Description: Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the the study, and then as frequently as they choose after the first week. There will be a payment of $30 during the first week for each day a participant uses CPAP for more than 4 hours the previous night and logs on to the website.
Study NCT03173261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Genexpert
Description: diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
Study NCT02250950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI and SDT Exercise Group
Description: The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.
Study NCT02250950 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Non-MI and SDT Exercise Group
Description: This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.
Study NCT00097838 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
Study NCT04453163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Description: Patient will undergo a surgery in percutaneous vertebroplasty
Study NCT04453163 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vertebroplasty
Description: Patient will undergo a surgery in percutaneous vertebroplasty
Study NCT02854371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadoxetic acid enhanced liver MRI
Description: Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.~Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution.
Study NCT02854371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG R15
Description: ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
Study NCT03061604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemospray
Description: Hemospray is a novel hemostatic powder licensed for endoscopic hemostasis of non-variceal upper gastrointestinal bleeding which has been shown to be effective in preliminary studies for the management of patients with peptic ulcer bleeding, including those on anticoagulant or antithrombotic therapy . Recently, two case reports and a pilot study reported that hemostatic powder may be useful in emergency management of variceal bleeding as a bridge towards more definitive therapy
Study NCT03061604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide will be administered to all patients at time of admission and will be continued for 24 hours~• Dosage: 50 mcg bolus at admission then 25 mcg/hour
Study NCT03061604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide will be administered to all patients at time of admission and will be continued for 24 hours~• Dosage: 50 mcg bolus at admission then 25 mcg/hour
Study NCT03061604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Blood transfusion will be administered to all patients if needed
Study NCT03061604 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Blood transfusion will be administered to all patients if needed
Study NCT03061604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Ceftriaxone will be administered to all patients on daily basis
Study NCT03061604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Ceftriaxone will be administered to all patients on daily basis
Study NCT02756598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil I
Description: bolus dose of sufentanil 1 microgram/kg
Study NCT02756598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil II
Description: bolus dose of sufentanil 0.5 microgram/kg
Study NCT02756598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol I
Description: Continued dose of propofol 0.03 mg/kg/min
Study NCT02756598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol II
Description: Continued dose of propofol 0.06 mg/kg/min
Study NCT01471275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 250 mg or 500mg three times a day
Study NCT01471275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jiangtangtiaozhi decoction
Description: 15 grams each time, twice a day, with boiled water
Study NCT03761004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbidopa-levodopa
Description: single dose of WD-1603, BID dose of WD-1603 and Sinemet IR
Study NCT03761004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa
Description: single dose of WD-1603, BID dose of WD-1603 and Sinemet IR
Study NCT03066778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion on Day 1 of each cycle prior to chemotherapy
Study NCT03066778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline solution
Description: IV infusion on Day 1 of each cycle prior to chemotherapy
Study NCT03066778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion on Day 1 of each cycle
Study NCT03066778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion on Day 1 of each cycle
Study NCT03066778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion on Day 1 of each cycle
Study NCT03066778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion on Day 1 of each cycle
Study NCT03066778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV infusion on Days 1, 2 and 3 of each cycle
Study NCT03066778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: IV infusion on Days 1, 2 and 3 of each cycle
Study NCT02508415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Therapy
Description: OHE, scaling root planing, mouth wash
Study NCT02734225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Recovery
Description: Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase
Study NCT02734225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Recovery
Description: Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase
Study NCT02734225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Balance and proprioception training using parallel bars, unstable plates, ramps and stairs
Study NCT02734225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance and proprioception training using parallel bars, unstable plates, ramps and stairs
Study NCT02734225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamometric Platform Training
Description: Stability tests, weight changes and stability limits, performing both anterior-posterior and medial-lateral movements simultaneously in some cases
Study NCT05262790 — intervention group
Intervention type: OTHER
Intervention: This is not an intervention study
Study NCT04186897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occlusal reduction
Description: Occlusal contacts on the functional and non-functional cusps were reduced.
Study NCT04186897 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham occlusal reduction
Description: The occlusal surface left intact. No actual occlusal reduction.
Study NCT03782805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol (Euro-Pharm International, Canada)
Description: The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
Study NCT03782805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
Study NCT03089801 — intervention group
Intervention type: OTHER
Intervention: Tablet-Enabled Video Telehealth
Description: Veterans referred for tablet-enabled video telehealth will receive a VA-issued tablet that can be used to communicate via video with health care providers (e.g., for chronic disease management, mental health treatment, palliative care).
Study NCT01464853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition with fatty acids
Description: Enteral Feeding to provide 25 kcal/Kg/day
Study NCT01464853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Enteral Nutrition
Description: Enteral Feeding to provide 25 kcal/Kg/day
Study NCT01756508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
Study NCT02570750 — intervention group
Intervention type: BEHAVIORAL
Intervention: QUESTIONNAIRE ON SMOKING HABITS
Description: Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis).~Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points.
Study NCT02372435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shortening of the interval of two-stage prosthesis exchange
Description: The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
Study NCT02372435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shortening of the interval of two-stage prosthesis exchange
Description: The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
Study NCT01865604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Study NCT01865604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal tDCS
Study NCT01865604 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Study NCT02463006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porous variant of Bioactive Glass.
Description: Flap surgery with Porous variant of Bioactive Glass.
Study NCT00607178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: Intramuscular injection of one 0.5-mL dose of influenza vaccine
Study NCT00607178 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo for influenza vaccine
Description: Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
Study NCT02463006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non porous variant of Bioactive Glass.
Description: Flap surgery with non-Porous variant of Bioactive Glass.
Study NCT04792047 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HRP frequency, plaque compostion and local immune-inflammatory activation
Description: HRP frequency, plaque compostion were detected by CCTA method. Local T cell subsets and their intracellular cytokines levels were detected by Flow Cytometry.
Study NCT04718311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral lichen clinical Healing evaluation
Description: Treatments were topically applied for 5 days
Study NCT04718311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral lichen clinical Healing evaluation
Description: Treatments were topically applied for 5 days
Study NCT02509793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrabenazine
Description: Xenazine, pill, dose to effect, three times a day, for 12 weeks
Study NCT03326232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
Study NCT01618461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug indication icons
Description: Icons illustrate the purpose of each medication
Study NCT01618461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured instructions
Description: Graphical format shows what time(s) of day each medication should be taken
Study NCT01304303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1023 I
Description: IV administration
Study NCT01304303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1023 II
Description: IV administration
Study NCT04719429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cricket-derived Protein
Description: Beverage containing 25 g cricket-derived protein
Study NCT04719429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beef-derived Protein
Description: Beverage containing 25 g beef-derived protein
Study NCT02192853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: In randomized order:~Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion
Study NCT02192853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 4: placebo tablet
Study NCT00791492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fx-1006A
Description: Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
Study NCT02232555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study NCT02232555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02588664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COMPASS Intervention
Description: * A Post-Acute Coordinator (PAC) will visit each patient prior to discharge from the hospital.~* Patient will receive a follow-up telephone call two days after having been discharged.~* 7-14 days after discharge, the patient will attend post-acute stroke clinic visit and receive an assessment from an Advanced Practice Provider (APP), a brief patient-reported functional assessment to generate an individualized Care Plan, and referrals from an APP. The patient's primary caregiver will be assessed to ensure caregiver availability and ability to support the patient and the caregiver's ability to cope with the new challenges of caregiving.~* Patient will receive a call at 30 and 60 days post-discharge for follow-up of functional status, recovery, risk factor management and their access or utilization of recommended services.
Study NCT03034135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram/Copper
Description: Disulfiram/copper gluconate is taken three times a day.
Study NCT03034135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: TMZ is given per standard of care
Study NCT00910546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: visicoil gold marker 0.7 x 20 mm
Description: CT - guided implantation into lung tumors
Study NCT02529098 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: fMRI
Description: functional magnetic resonance imaging
Study NCT02529098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: functional magnetic resonance imaging
Study NCT00600158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine with hydromorphone
Description: bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h
Study NCT00600158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: lidocaine 2 mg/min intravenously (or 3 mg/kg in patients > 70 kg)
Study NCT02966821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
Study NCT01239082 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy
Description: One time screening Colonoscopy to screen for colorectal cancer
Study NCT01239082 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FIT
Description: Annual FIT testing
Study NCT04402450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided suprainguinal fascia iliaca nerve block
Description: After an ultrasound-guided insertion of a block needle below the inguinal ligament, the needle will be advance in the plane between fascia iliaca and iliopsoas muscle up to a point cranial to the ligament in order to inject a 40 mL of adrenalized 0.25% levobupivacaine.
Study NCT04402450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pericapsular nerves group of the hip block
Description: After an ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% levobupivacaine.
Study NCT01430117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Four different concentrations of Poa pratensis allergen extract, positive control and negative control
Description: Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
Study NCT03991988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Participants in this arm will take a pill of Montelukast daily on escalating doses: 10, 20 to 40 mg.~All participants will be initiated on 10 mg. The dose will be increased in 2-week increments to 20 mg and 40 mg as long as participants report no intolerable symptoms or adverse events.
Study NCT01140828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: Rabeprazole 20mg once daily
Study NCT01140828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole Placebo
Description: one tab once daily
Study NCT00462176 — intervention group
Intervention type: PROCEDURE
Intervention: multidisciplinary laparoscopy
Description: Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.
Study NCT00462176 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).
Study NCT00682994 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interview
Description: Interview lasting about 5-10 minutes.
Study NCT00682994 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaires taking 20-30 minutes to complete.
Study NCT03885999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fecobionics
Description: Fecobionics is a new device for studying defecation
Study NCT01403259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin
Description: S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks
Study NCT03991988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Participants in this arm will take a matched placebo pill daily